Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
Abstract Background Shorter duration of symptoms before remdesivir has been associated with better outcomes. Our goal was to evaluate variables associated with the need of ICU admission in a cohort of hospitalized patients for COVID-19 under remdesivir including the period from symptoms onset to rem...
Κύριοι συγγραφείς: | Rodrigo Alonso-Navarro, Margarita Ramírez, Mar Masiá, Roger Paredes, Rocío Montejano, Marina Povar-Echeverria, Jordi Carratalà, Miguel Salavert, Enrique Bernal, Carlos Dueñas, Juan Flores, Francisco Fanjul, Isabel Gutiérrez, Verónica Rico, Lourdes Mateu, Julen Cadiñanos, Juan Berenguer, Alex Soriano |
---|---|
Μορφή: | Άρθρο |
Γλώσσα: | English |
Έκδοση: |
BMC
2023-05-01
|
Σειρά: | BMC Infectious Diseases |
Θέματα: | |
Διαθέσιμο Online: | https://doi.org/10.1186/s12879-023-08222-y |
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Remdesivir administration for SARS-CoV-2 pneumonia in ICU and non-ICU patients: outcome and posttreatment differences — the Italian Military Hospital experience
ανά: Antonio Sabba, κ.ά.
Έκδοση: (2023-09-01) -
The effect of remdesivir on mortality and the outcome of patients with COVID‐19 in intensive care unit: A case–control study
ανά: Mehran Amirizadeh, κ.ά.
Έκδοση: (2023-11-01) -
The use of Remdesivir in pregnant women with COVID-19
ανά: Gulbanu Shaimerdenova, κ.ά.
Έκδοση: (2023-02-01) -
Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven
ανά: Richard D. Shih, κ.ά.
Έκδοση: (2020-12-01) -
Publicaciones sobre hidroxicloroquina y remdesivir: actualización septiembre 2020
ανά: Flor álvarez de Toledo
Έκδοση: (2020-10-01)